A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Multi-dose Study to Evaluate Safety and Efficacy of ASC40 Tablets in Subjects With Moderate to Severe Acne Vulgaris
Latest Information Update: 02 May 2024
At a glance
- Drugs Denifanstat (Primary)
- Indications Acne vulgaris
- Focus Therapeutic Use
- Sponsors Ascletis
- 12 Mar 2024 Final results assessing safety and efficacy of ASC40 presented at the American Academy of Dermatology annual Meeting 2024.
- 10 Mar 2024 According to Ascletis media release, the company to present final data form this study at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, the United States.
- 10 Mar 2024 Results published in an Ascletis media release.